Fabry Disease Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Protalix Biotherapeutics, Sanofi, 4D Molecular therapeutics, Ozmosis Research, AvroBio and Others

Fabry Disease Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Protalix Biotherapeutics, Sanofi, 4D Molecular therapeutics, Ozmosis Research, AvroBio and Others

“Fabry Disease Pipeline”

Fabry Disease is a rare genetic disorder that prevents the body from making an enzyme called alpha-galactosidase A. This enzyme is responsible for breaking down a type of fat called globotriaosylceramide (Gb3 or GL-3) into building blocks that the body’s cells can use. Fabry Disease can have many symptoms because it affects cells throughout the body. The symptoms include: Chronic pain — usually a burning or tingling sensation — in the hands and feet, Clusters of small, dark red spots in various locations on the skin, Opaque corneas, resulting in cloudy-looking eyes and problems with eyesight, Ringing in the ears, and hearing loss. Fabry Disease is caused by a mutation of the GLA gene, which encodes for the alpha-galactosidase A enzyme. The mutation usually makes the enzyme unable to function, although in mild cases, it may function to some degree. The disease is inherited in an X-linked dominant manner, which means that the gene involved is situated on the X chromosome.

DelveInsight’s, Fabry Disease Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Fabry Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

 

Request for Free Sample Pages: https://www.delveinsight.com/sample-request/fabry-disease-pipeline-insight

 

Some of Fabry Disease Companies are:

  • Protalix Biotherapeutics
  • Sanofi
  • 4D Molecular therapeutics
  • Ozmosis Research Inc.
  • AvroBio
  • Freeline Therapeutics
  • Sangamo Therapeutics
  • Translate Bio
  • Abeona Therapeutics
  • AVROBIO
  • Sangamo Therapeutics
  • And Many Others

 

Request for Free Sample Pages: https://www.delveinsight.com/sample-request/fabry-disease-pipeline-insight

 

DelveInsight’s Fabry Disease report covers around 15+ products under different phases of clinical development like:

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Some of Fabry Disease Drugs are:

  • Venglustat
  • Pegunigalsidase alfa
  • 4D 310
  • And Many Others

 

Fabry Disease Report Key Questions:

  • How many companies are developing Fabry Disease drugs?
  • How many Fabry Disease drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Fabry Disease?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Fabry Disease therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Fabry Disease and their status?
  • What are the key designations that have been granted to the emerging drugs?

 

Request for Free Sample Pages: https://www.delveinsight.com/sample-request/fabry-disease-pipeline-insight

 

Table of Contents:

Introduction

Executive Summary

Fabry Disease: Overview

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

Fabry Disease – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

  • Fabry Disease companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Fabry Disease Collaboration Deals

Late Stage Products (Preregistration)

  • Comparative Analysis

Pegunigalsidase alfa: Protalix Biotherapeutics

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

Venglustat: Sanofi

Drug profiles in the detailed report…..

Early Stage Products (Phase I/II)

  • Comparative Analysis

4D 310: 4D Molecular Therapeutics

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Fabry Disease Key Companies

Fabry Disease Key Products

Fabry Disease- Unmet Needs

Fabry Disease- Market Drivers and Barriers

Fabry Disease- Future Perspectives and Conclusion

Fabry Disease Analyst Views

Fabry Disease Key Companies

Appendix

Request for Deatiled TOC: https://www.delveinsight.com/sample-request/fabry-disease-pipeline-insight

 

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/fabry-disease-pipeline-insight